Gonadotropin-releasing hormone agonists, anti-androgens and the risk of cardio-cerebrovascular disease in prostate cancer patients : an asian population-based observational study
© The author(s)..
Purpose: To conduct a population-based study to determine whether the use of GnRH agonist and antiandrogens are associated with an increased risk of cardio-cerebrovascular disease (CCVD) in Asian patients with prostate cancer using the National Health Insurance Service-Elderly Cohort Database (NHIS-ECD). Materials and Methods: We included a total of 2,413 men aged 60 years or older with prostate cancer between January 2003 and December 2008. Outcomes of interest included the first occurrence of cardiovascular events [acute myocardial infarction (AMI), ischemic heart disease (IHD)] and cerebrovascular events [ischemic stroke (IS), and cerebrovascular disease (CVD)]. Results: The 5-year AMI-free rates of patients diagnosed with prostate cancer and treated with GnRH agonists, antiandrogens alone, or androgen deprivation therapy (ADT)-naïve interventions were 97.0%, 96.5%, and 98.3%, respectively, while the 5-year IHD-free rates were 93.2%, 92.3%, and 94.5%, respectively. Exposure to GnRH agonists or antiandrogen regimens did not significantly increase the risk of AMI or IHD compared to ADT-naïve treatment in multivariate Cox proportional-hazards models after adjusting for other covariates. Five-year IS-free rates of patients exposed to GnRH agonists, antiandrogens alone, and those with ADT-naïve prostate cancer were 94.8%, 94.7%, and 95.5%, respectively, while the five-year CVD-free rates were 92.9%, 93.3%, and 94.6%, respectively. Cox proportional-hazards models also failed to show that men who received GnRH agonist or antiandrogen treatment alone carried a significantly increased risk for IS or CVD compared to ADT-naïve patients. Conclusions: The current study based on Asian population suggests that treatment with neither GnRH agonist nor antiandrogens increases the risk of cardio-cerebrovascular disease compared to patients with ADT-naïve prostate cancer.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
---|---|
Enthalten in: |
Journal of Cancer - 11(2020), 14 vom: 11., Seite 4015-4022 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Seong, Jong-Mi [VerfasserIn] |
---|
Links: |
---|
Themen: |
Antiandrogens |
---|
Anmerkungen: |
Date Revised 28.09.2020 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.7150/jca.38237 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM309518172 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM309518172 | ||
003 | DE-627 | ||
005 | 20231225134105.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.7150/jca.38237 |2 doi | |
028 | 5 | 2 | |a pubmed24n1031.xml |
035 | |a (DE-627)NLM309518172 | ||
035 | |a (NLM)32368283 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Seong, Jong-Mi |e verfasserin |4 aut | |
245 | 1 | 0 | |a Gonadotropin-releasing hormone agonists, anti-androgens and the risk of cardio-cerebrovascular disease in prostate cancer patients |b an asian population-based observational study |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 28.09.2020 | ||
500 | |a published: Electronic-eCollection | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
520 | |a © The author(s). | ||
520 | |a Purpose: To conduct a population-based study to determine whether the use of GnRH agonist and antiandrogens are associated with an increased risk of cardio-cerebrovascular disease (CCVD) in Asian patients with prostate cancer using the National Health Insurance Service-Elderly Cohort Database (NHIS-ECD). Materials and Methods: We included a total of 2,413 men aged 60 years or older with prostate cancer between January 2003 and December 2008. Outcomes of interest included the first occurrence of cardiovascular events [acute myocardial infarction (AMI), ischemic heart disease (IHD)] and cerebrovascular events [ischemic stroke (IS), and cerebrovascular disease (CVD)]. Results: The 5-year AMI-free rates of patients diagnosed with prostate cancer and treated with GnRH agonists, antiandrogens alone, or androgen deprivation therapy (ADT)-naïve interventions were 97.0%, 96.5%, and 98.3%, respectively, while the 5-year IHD-free rates were 93.2%, 92.3%, and 94.5%, respectively. Exposure to GnRH agonists or antiandrogen regimens did not significantly increase the risk of AMI or IHD compared to ADT-naïve treatment in multivariate Cox proportional-hazards models after adjusting for other covariates. Five-year IS-free rates of patients exposed to GnRH agonists, antiandrogens alone, and those with ADT-naïve prostate cancer were 94.8%, 94.7%, and 95.5%, respectively, while the five-year CVD-free rates were 92.9%, 93.3%, and 94.6%, respectively. Cox proportional-hazards models also failed to show that men who received GnRH agonist or antiandrogen treatment alone carried a significantly increased risk for IS or CVD compared to ADT-naïve patients. Conclusions: The current study based on Asian population suggests that treatment with neither GnRH agonist nor antiandrogens increases the risk of cardio-cerebrovascular disease compared to patients with ADT-naïve prostate cancer | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Antiandrogens | |
650 | 4 | |a Cardiovascular Diseases | |
650 | 4 | |a Cerebrovascular Disease | |
650 | 4 | |a Gonadotropin-Releasing Hormone | |
650 | 4 | |a Prostatic Neoplasms | |
700 | 1 | |a Shin, Dongho |e verfasserin |4 aut | |
700 | 1 | |a Sung, Jae Woo |e verfasserin |4 aut | |
700 | 1 | |a Cho, Shinjay |e verfasserin |4 aut | |
700 | 1 | |a Yang, Jonghyup |e verfasserin |4 aut | |
700 | 1 | |a Kang, Sungmin |e verfasserin |4 aut | |
700 | 1 | |a Moon, Hyong Woo |e verfasserin |4 aut | |
700 | 1 | |a Lee, Kyu Won |e verfasserin |4 aut | |
700 | 1 | |a Ha, U-Syn |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of Cancer |d 2010 |g 11(2020), 14 vom: 11., Seite 4015-4022 |w (DE-627)NLM201575388 |x 1837-9664 |7 nnns |
773 | 1 | 8 | |g volume:11 |g year:2020 |g number:14 |g day:11 |g pages:4015-4022 |
856 | 4 | 0 | |u http://dx.doi.org/10.7150/jca.38237 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 11 |j 2020 |e 14 |b 11 |h 4015-4022 |